Journal of Experimental Medicine (JEM) | Rockefeller University Press

Skip Nav Destination

JEM Clinical Immunology 2022.
JEM Stem Cell Collection 2022.
Adaptive resistance to RET inhibition.
Arctic IFNAR2 viral susceptibility variant.
Earn Continuing Medical Education (CME) in this new activity with Memorial Sloan Kettering. Learn more.

RUP response to COVID-19 crisis: Learn about the steps we are taking and find relevant content.

Newest Articles

Article

| June 27 2022

IL-12–mediated human NK cell memory-like expansion

Avishai Shemesh, Harry Pickering, Kole T. Roybal, Lewis L. Lanier

Low IL-12 concentrations are sufficient to induce expansion of human NK cells by innate-activating NK receptor-orchestrated differential IL-12 signaling.

Technical Advances and Resources

| June 23 2022

Antimalarial antibodies with enhanced protection

Bailey B. Banach, Prabhanshu Tripathi, Lais Da Silva Pereira, Jason Gorman, Thuy Duong Nguyen, Marlon Dillon, Ahmed S. Fahad, Patience K. Kiyuka, Bharat Madan, Jacy R. Wolfe, Brian Bonilla, Barbara Flynn, Joseph R. Francica, Nicholas K. Hurlburt, Neville K. Kisalu, Tracy Liu, Li Ou, Reda Rawi, Arne Schön, Chen-Hsiang Shen, I-Ting Teng, Baoshan Zhang, Marie Pancera, Azza H. Idris, Robert A. Seder, Peter D. Kwong, Brandon J. DeKosky

This study applied innovative antibody screening technologies to discover antimalarial antibody variants with enhanced protective potency. Study authors applied precision DNA library generation, high-throughput screening, and analysis of next generation sequencing data to identify mutations that improved malaria protection following in vivo infectious challenge.

Brief Definitive Report

| June 16 2022

Type I IFN defect in children with COVID pneumonia

Qian Zhang, Daniela Matuozzo et al.

In an international cohort of 112 children hospitalized for moderate to critical COVID-19 pneumonia, we identified 12 children with one of four known recessive inborn errors of type I interferon immunity: X-linked TLR7 and autosomal IFNAR1, STAT2, and TYK2 deficiencies.

Article

| June 15 2022

MPS IIIC knock-in mice respond to glucosamine

Xuefang Pan, Mahsa Taherzadeh, Poulomee Bose, Rachel Heon-Roberts, Annie L.A. Nguyen, TianMeng Xu, Camila Pará, Yojiro Yamanaka, David A. Priestman, Frances M. Platt, Shaukat Khan, Nidhi Fnu, Shunji Tomatsu, Carlos R. Morales, Alexey V. Pshezhetsky

The study demonstrates that dominant-negative effects of the misfolded HGSNAT variant in the mouse model of mucopolysaccharidosis IIIC are treatable by glucosamine. This suggests that patients affected with mutations causing the enzyme misfolding can potentially benefit from chaperone therapy.

Article

| June 15 2022

Broadly SARS-CoV-2–neutralizing antibodies

Cyril Planchais, Ignacio Fernández, Timothée Bruel, Guilherme Dias de Melo, Matthieu Prot, Maxime Beretta, Pablo Guardado-Calvo, Jérémy Dufloo, Luis M. Molinos-Albert, Marija Backovic, Jeanne Chiaravalli, Emilie Giraud, Benjamin Vesin, Laurine Conquet, Ludivine Grzelak, Delphine Planas, Isabelle Staropoli, Florence Guivel-Benhassine, Thierry Hieu, Mikaël Boullé, Minerva Cervantes-Gonzalez, Marie-Noëlle Ungeheuer, Pierre Charneau, Sylvie van der Werf, Fabrice Agou, French COVID Cohort Study Group, CORSER Study Group, Jordan D. Dimitrov, Etienne Simon-Lorière, Hervé Bourhy, Xavier Montagutelli, Félix A. Rey, Olivier Schwartz, Hugo Mouquet

This study identifies broadly SARS-CoV-2–neutralizing IgA and IgG antibodies from Wuhan COVID-19 convalescents active against the variants of concern Alpha, Beta, Gamma, Delta, and Omicron BA.1 and BA.2.

Article

| June 14 2022

Context-dependent effects of IL-2

Carly E. Whyte, Kailash Singh, Oliver T. Burton, Meryem Aloulou, Lubna Kouser, Rafael Valente Veiga, Amy Dashwood, Hanneke Okkenhaug, Samira Benadda, Alena Moudra, Orian Bricard, Stephanie Lienart, Pascal Bielefeld, Carlos P. Roca, Francisco José Naranjo-Galindo, Félix Lombard-Vadnais, Steffie Junius, David Bending, Tino Hochepied, Timotheus Y.F. Halim, Susan Schlenner, Sylvie Lesage, James Dooley, Adrian Liston

Network analysis of IL-2 identifies a context-dependent hierarchy of consumption and response. IL-2 sourced from different leukocytes drives different circuits of responding cells, independent of concentration. Targeting IL-2 localization may therefore allow fine-tuning of therapeutic responses.

Article

| June 10 2022

CCL17 is a therapeutic target for heart failure

Yang Zhang, Yicong Ye, Xiaoqiang Tang, Hui Wang, Toshiko Tanaka, Ran Tian, Xufei Yang, Lun Wang, Ying Xiao, Xiaomin Hu, Ye Jin, Haiyu Pang, Tian Du, Honghong Liu, Lihong Sun, Shuo Xiao, Ruijia Dong, Luigi Ferrucci, Zhuang Tian, Shuyang Zhang

Zhang et al. identified chemokine CCL17 as a contributor to age-related heart failure in humans and mice via regulating plasticity and differentiation of T cells. Their findings suggested CCL17 as a novel therapeutic target in age-related heart failure.

Browse All >

Related Articles from Rockefeller University Press

Current Issue

Volume 219,

Issue 6,

6 June 2022

View This Issue

Submit Your Research

Manage Email Alerts

Reviews & Opinions

Perspective

| June 22 2022

Dense-core plaques are granulomas

Greg Lemke, Youtong Huang

Microglia, the tissue macrophages of the central nervous system, use phagocytosis of loosely organized amyloid beta (Aβ) to construct dense-core plaques, one of the defining histopathological features of Alzheimer’s disease. The biology of this process parallels macrophage construction of granulomas in tuberculosis and other settings.

Insights

| May 27 2022

Fueling the fire in the gut

Chia-Hao Lin, Li-Fan Lu

Gut dysbiosis has long been associated with the development of Crohn's disease and other gastrointestinal disorders. Otake-Kasamoto et al. report that dysbiotic microbiota–derived bioactive lipids, lysophosphatidylserines, can promote pathological Th1 cell responses through inducing metabolic reprogramming and epigenetic changes.

Review

| May 23 2022

Realigning LIGHT in dysregulated inflammation

Carl F. Ware, Michael Croft, Garry A. Neil

The cytokine LIGHT (TNFSF14) has emerged as an important modulator of innate and adaptive immune responses. Accumulating basic and clinical evidence points to the dysregulation of the LIGHT network as a disease-driving mechanism and supports the application of target-modifying therapeutics for disease intervention.

Browse All

Special Collections

The Year in Experimental Medicine

Our annual Best of JEM series, featuring articles that were of great interest to our readers..

View all collections

JEM Clinical Immunology 2022.

JEM Stem Cell Collection 2022.

Adaptive resistance to RET inhibition.

Arctic IFNAR2 viral susceptibility variant.

Earn Continuing Medical Education (CME) in this new activity with Memorial Sloan Kettering. Learn more.

Related Articles from Rockefeller University Press

Most Read

Special Collections

This Feature Is Available To Subscribers Only